Company news
Liquidia Corporation (NASDAQ:LQDA) news
Liquidia Corporation news releases on 6ix. Latest, Sep 30, 2026: Liquidia Provides Update on Hatch-Waxman Litigation Tied to ‘327 Patent
Press releases & updates
Liquidia Provides Update on Hatch-Waxman Litigation Tied to ‘327 Patent
September 30, 2026
Liquidia Provides Update on Hatch-Waxman Litigation Tied to ‘327 Patent
September 29, 2026
FDA Grants Fast Track Designation to YUTREPIA® for the Treatment of Raynaud's Phenomenon Associated with Systemic Sclerosis
September 3, 2026
Liquidia to Present Posters at the European Respiratory Society (ERS) 2026 Congress
September 2, 2026
Liquidia Corporation to Participate in Wells Fargo Annual Healthcare Conference
September 1, 2026
Liquidia Corporation Reports Second Quarter 2026 Financial Results
August 12, 2026
Liquidia Corporation to Report Second Quarter 2026 Financial Results on August 12, 2026
July 29, 2026
Liquidia Announces Poster Presentations at the PHA 2026 International PH Conference and Scientific Sessions
June 11, 2026
Liquidia Corporation Announces Inclusion in the S&P SmallCap 600® Index
June 8, 2026
Liquidia Corporation to Present at 2026 Jefferies Global Healthcare Conference
May 26, 2026
Liquidia Corporation Reports First Quarter 2026 Financial Results
May 11, 2026
Liquidia Corporation to Report First Quarter 2026 Financial Results on May 11, 2026
May 4, 2026
Liquidia Corporation to Participate in Upcoming Investor Conferences
April 7, 2026
Liquidia Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
March 4, 2026
Liquidia Corporation to Report Full Year 2025 Financial Results on March 5, 2026
February 25, 2026
Liquidia to Present Clinical Data Across Its Portfolio at the Pulmonary Vascular Research Institute 2026 Annual Congress
January 27, 2026
Liquidia Corporation Announces Preliminary Full-Year 2025 YUTREPIA Net Sales and Corporate Update
January 9, 2026
Liquidia Corporation to Present at 44th Annual J.P. Morgan Healthcare Conference
January 6, 2026
Liquidia Corporation Reports Third Quarter 2025 Financial Results and Provides Corporate Update
November 2, 2025
Liquidia Corporation to Present at Upcoming Healthcare Investment Conferences
November 2, 2025
Liquidia Corporation to Report Third Quarter 2025 Financial Results on November 3, 2025
October 26, 2025
Liquidia Corporation to Host R&D Day in New York City on October 28, 2025
October 6, 2025
Liquidia to Present Clinical Data from ASCENT Trial at the CHEST 2025 Annual Meeting
September 28, 2025
Liquidia Announces Poster Presentations at the Pulmonary Hypertension Professional Association (PHPN) Symposium
September 10, 2025
Liquidia Corporation to Present at the 2025 Wells Fargo Healthcare Conference
August 26, 2025
Liquidia Corporation Reports Second Quarter 2025 Financial Results and Provides Corporate Update
August 11, 2025
Liquidia Corporation to Report Second Quarter 2025 Financial Results on August 12, 2025
August 4, 2025
Liquidia Receives $50 Million from Healthcare Royalty (HCRx) Following First Commercial Sale of YUTREPIA™
June 22, 2025
Liquidia Schedules First Commercial Shipment of YUTREPIA™ (treprostinil) Inhalation Powder for Patients with PAH and PH-ILD
June 1, 2025
Liquidia Corporation to Present at the 2025 Jefferies Global Healthcare Conference
May 27, 2025
U.S. FDA Approves Liquidia’s YUTREPIA™ (treprostinil) Inhalation Powder for Patients with Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)
May 22, 2025
Liquidia Corporation Provides Update on Litigation Filed by United Therapeutics
May 11, 2025
Liquidia Corporation Reports First Quarter 2025 Financial Results and Provides Corporate Update
May 7, 2025
Liquidia Corporation to Present at BofA Securities 2025 Health Care Conference
May 5, 2025
District Court Dismisses Dispute Filed by United Therapeutics Against Liquidia
May 1, 2025
Liquidia Corporation to Report First Quarter 2025 Financial Results on May 8, 2025
April 30, 2025
UPDATE – Liquidia Corporation to Present at the 24th Annual Needham Virtual Healthcare Conference
April 1, 2025
Liquidia Corporation to Present at the 24th Annual Needham Virtual Healthcare Conference
March 31, 2025
Liquidia Corporation Announces FDA Acceptance of New Drug Application Resubmission for YUTREPIA™ (treprostinil) Inhalation Powder
March 27, 2025
Liquidia Announces Poster Presentations at the American Thoracic Society (ATS) 2025 International Conference
March 26, 2025
Liquidia Corporation Reports Full Year 2024 Financial Results and Provides Corporate Update
March 18, 2025
Liquidia Corporation Strengthens Financial Position by Amending HealthCare Royalty Agreement to Incrementally Add Up to $100 Million
March 17, 2025
Liquidia Corporation to Report Full Year 2024 Financial Results on March 19, 2025
March 11, 2025
Liquidia Corporation to Present at 43rd Annual J.P. Morgan Healthcare Conference
January 7, 2025
Liquidia Corporation Reports Third Quarter 2024 Financial Results and Provides Corporate Update
November 12, 2024
Liquidia to Present at the Stifel 2024 Healthcare Conference
November 11, 2024
Liquidia Corporation to Report Third Quarter 2024 Financial Results on November 13, 2024
November 5, 2024
Liquidia Corporation to Report Third Quarter 2024 Financial Results on November 11, 2024
November 3, 2024
United States Supreme Court Declines to Review Rulings that Invalidate United Therapeutics’ Patent
October 6, 2024
Liquidia and Pharmosa Biopharm Expand Collaboration to Develop Sustained Release Inhaled Treprostinil (L606)
October 1, 2024